SCHEMBL607474

SCHEMBL607474

COc1ccc(CN2CCN(CC(O)Cn3c4ccccc4c4ccccc43)CC2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 1.00
MAPK1 P28482 4/20 1.00
HTT P42858 3/20 1.00
MAPT P10636 4/20 0.79
SMN1; SMN2 Q16637 3/20 0.79
GAA P10253 1/20 0.75
DNM1 Q05193 1/20 0.61
POLB P06746 2/20 0.59
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
SIGMAR1 Q99720 1/20 0.57
ATM Q13315 1/20 0.56
RAD52 P43351 1/20 0.55
SMPD1 P17405 1/20 0.55
ALDH1A1 P00352 2/20 0.54
HPGD P15428 2/20 0.54
KDM4E B2RXH2 1/20 0.54
TP53 P04637 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
BACE1 P56817 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL607384 0.91 LMNA (0.82) LMNAMAPK1HTTMAPTSMN1; SMN2
SCHEMBL607881 0.86 LMNA (1.00) LMNAMAPK1HTTMAPTSMN1; SMN2
SCHEMBL607488 0.85 LMNA (0.82) LMNAMAPK1HTTMAPTSMN1; SMN2
SCHEMBL605724 0.84 MAPK1 (0.72) LMNAMAPK1HTTMAPTSMN1; SMN2
SCHEMBL5022683 0.84 MAPK1 (0.72) LMNAMAPK1HTTMAPTSMN1; SMN2
SCHEMBL605725 0.84 MAPK1 (0.72) LMNAMAPK1HTTMAPTSMN1; SMN2
SCHEMBL608283 0.84 LMNA (0.81) LMNAMAPK1HTTMAPTSMN1; SMN2
SCHEMBL609395 0.83 LMNA (0.75) LMNAMAPK1HTTMAPTSMN1; SMN2
SCHEMBL6815269 0.82 POLB (0.84) LMNAMAPK1HTTMAPTSMN1; SMN2
SCHEMBL5028632 0.81 LMNA (0.72) LMNAMAPK1HTTMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008147864-A2 METHODS OF USING PIPERAZINE COMPOUNDS IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS XENON PHARMACEUTICALS INC. (CA) 2008-12-04 WO claimed
EP-1237887-B1 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS SERONO LAB (CH) 2008-06-04 EP claimed
US-8410110-B2 9-(piperazinylalkyl) carbazoles as Bax-modulators MERCK SERONO SA (CH) 2013-04-02 US disclosed
US-20120040933-A1 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2012-02-16 US disclosed
US-8053436-B1 9-(piperazinylalkyl) carbazoles as bax-modulators MERCK SERONO SA (CH) 2011-11-08 US disclosed
EP-1237887-B1 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS SERONO LAB (CH) 2008-06-04 EP disclosed
EP-1237887-A1 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS Applied Research Systems ARS Holding N.V. (AN) 2002-09-11 EP disclosed
WO-2001029028-A1 9- (PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2001-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040933-A1 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS BCL2, BAX, BAD LMNA 55/4885MAPK1 3036/4885HTT 65/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.